AU784338B2 - Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same - Google Patents
Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same Download PDFInfo
- Publication number
- AU784338B2 AU784338B2 AU14493/01A AU1449301A AU784338B2 AU 784338 B2 AU784338 B2 AU 784338B2 AU 14493/01 A AU14493/01 A AU 14493/01A AU 1449301 A AU1449301 A AU 1449301A AU 784338 B2 AU784338 B2 AU 784338B2
- Authority
- AU
- Australia
- Prior art keywords
- expression
- antibody
- nucleic acid
- acid sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16269999P | 1999-11-01 | 1999-11-01 | |
US60/162669 | 1999-11-01 | ||
US19680200P | 2000-04-13 | 2000-04-13 | |
US60/196802 | 2000-04-13 | ||
US70335000A | 2000-10-31 | 2000-10-31 | |
US09/703350 | 2000-10-31 | ||
PCT/US2000/030051 WO2001032926A2 (fr) | 1999-11-01 | 2000-11-01 | Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006202570A Division AU2006202570A1 (en) | 1999-11-01 | 2006-06-16 | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
AU1449301A AU1449301A (en) | 2001-05-14 |
AU784338B2 true AU784338B2 (en) | 2006-03-16 |
Family
ID=27388787
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU14493/01A Ceased AU784338B2 (en) | 1999-11-01 | 2000-11-01 | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
AU2006202570A Abandoned AU2006202570A1 (en) | 1999-11-01 | 2006-06-16 | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006202570A Abandoned AU2006202570A1 (en) | 1999-11-01 | 2006-06-16 | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2003525595A (fr) |
AU (2) | AU784338B2 (fr) |
CA (1) | CA2389751A1 (fr) |
WO (1) | WO2001032926A2 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2798674B1 (fr) * | 1999-09-21 | 2004-01-30 | Mahmood Salman Al | Procede d'identification de nouveaux genes impliques dans la regulation de l'angiogenese, etude de ces genes et leur utilisation a des fins therapeutiques |
EP1415987B1 (fr) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Composes heteroaromatiques azotes pour le traitement des maladies de cancer |
CA2461372C (fr) * | 2001-09-27 | 2014-01-07 | Bionomics Limited | Sequences d'adn destinees aux genes humains de l'angiogenese |
WO2004039955A2 (fr) | 2002-10-29 | 2004-05-13 | Rigel Pharmaceuticals, Inc. | Modulateurs de l'angiogenese et de la tumorigenese |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
US7407660B2 (en) | 2003-04-16 | 2008-08-05 | Genentech, Inc. | Methods and compositions for selective modulation of vascularization |
WO2005015227A1 (fr) * | 2003-08-08 | 2005-02-17 | Roche Diagnostics Gmbh | Proteine t-plastine (plst) utilisee comme marqueur du cancer colorectal |
WO2005015226A1 (fr) * | 2003-08-08 | 2005-02-17 | Roche Diagnostics Gmbh | Utilisation de la plastine t de proteine (plst) comme marqueur du cancer colono-rectal |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
EP1721158A4 (fr) * | 2004-01-13 | 2008-07-30 | Rigel Pharmaceuticals Inc | Modulateurs d'angiogenese |
JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
JP2006333770A (ja) * | 2005-06-01 | 2006-12-14 | Japan Science & Technology Agency | 血管炎(angiitis)患者の血液細胞特異的遺伝子群 |
JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
WO2007022625A1 (fr) * | 2005-08-22 | 2007-03-01 | Caprion Pharmaceuticals Inc. | Procedes de reversion d'expression peptidique, et utilisations |
CA2627598C (fr) | 2005-11-07 | 2013-06-25 | Eisai R & D Management Co., Ltd. | Utilisation d'une combinaison de substance anti-angiogenique et d'inhibiteur de kinase c-kit |
JP5190361B2 (ja) | 2006-05-18 | 2013-04-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 甲状腺癌に対する抗腫瘍剤 |
WO2007134718A2 (fr) * | 2006-05-18 | 2007-11-29 | Sanofi-Aventis | Utilisation du gène adamts4 et de polymorphismes de protéines |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
AU2008211952B2 (en) | 2007-01-29 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
CA2802644C (fr) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Agent anticancereux utilisant des composes ayant un effet inhibiteur de kinase en combinaison |
CA2828946C (fr) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Agent therapeutique pour les tumeurs |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
WO2014098176A1 (fr) | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Forme amorphe de dérivé de quinoline et son procédé de production |
EA201591894A1 (ru) | 2013-05-10 | 2016-04-29 | Орхус Университет | Регулятор паппализина |
KR102204279B1 (ko) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지 |
MX2017001980A (es) | 2014-08-28 | 2017-05-04 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y metodo para su produccion. |
BR112017017428A2 (pt) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | ?método para supressão do amargor de derivado de quinolina? |
KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
JP6757959B2 (ja) | 2015-06-16 | 2020-09-23 | 株式会社 PRISM BioLab | 抗がん剤 |
US20200129637A1 (en) | 2017-04-20 | 2020-04-30 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
WO2024037387A1 (fr) * | 2022-08-19 | 2024-02-22 | Tianjin Yunjian Medical Technology Co., Ltd. | Biomarqueurs sanguins et procédés de diagnostic de la maladie de kawasaki aiguë |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4373993A (en) * | 1992-05-14 | 1993-12-13 | Ohio State University Research Foundation, The | Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors |
WO1997030065A1 (fr) * | 1996-02-16 | 1997-08-21 | Millennium Pharmaceuticals, Inc. | Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires |
DE19701607A1 (de) * | 1997-01-17 | 1998-07-23 | Hoechst Ag | Anitkörper, die an die Nidogen-Bindungsdomäne des Laminins binden, deren Herstellung und Verwendung |
EP1070727A1 (fr) * | 1999-03-01 | 2001-01-24 | Aventis Pharma Deutschland GmbH | Peptides à bas poids moléculaire comme inhibiteurs de l'interaction laminine/nidogene |
AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
CA2387685A1 (fr) | 1999-10-27 | 2001-05-03 | Human Genome Sciences, Inc. | Proteines et acides nucleiques de stanniocalcine et methodes afferentes |
CA2403515A1 (fr) * | 2000-03-29 | 2001-10-04 | Beth Israel Deaconess Medical Center, Inc. | Proprietes anti-angiogenes et anti-tumorales de la vascostatine et d'autres domaines nidogenes |
-
2000
- 2000-11-01 WO PCT/US2000/030051 patent/WO2001032926A2/fr active Application Filing
- 2000-11-01 CA CA002389751A patent/CA2389751A1/fr not_active Abandoned
- 2000-11-01 AU AU14493/01A patent/AU784338B2/en not_active Ceased
- 2000-11-01 JP JP2001535606A patent/JP2003525595A/ja active Pending
-
2006
- 2006-06-16 AU AU2006202570A patent/AU2006202570A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001032926A3 (fr) | 2002-12-05 |
WO2001032926A2 (fr) | 2001-05-10 |
CA2389751A1 (fr) | 2001-05-10 |
JP2003525595A (ja) | 2003-09-02 |
AU1449301A (en) | 2001-05-14 |
AU2006202570A1 (en) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU784338B2 (en) | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same | |
US20080241835A1 (en) | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same | |
CA2322792C (fr) | Polypeptides homologues de vegf et bmp1 | |
EP1294876B1 (fr) | Acides nucleiques eg-vegf et polypeptides et leurs procedes d'utilisation | |
US20050202008A1 (en) | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs | |
AU768694B2 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
JP2012246296A (ja) | 血管形成及び心血管疾患の調節に使用する肝細胞成長因子の新規インヒビター | |
JP2009019032A (ja) | 血管形成及び心臓血管新生の促進又は阻害 | |
JP2003511028A (ja) | 新規ポリペプチド、その核酸および新脈管形成および血管新生におけるその使用のための方法 | |
WO1999014234A2 (fr) | Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation | |
WO2001040464A1 (fr) | Kinase 3 associee au recepteur de l'interleukine 1 (irak3) et son utilisation pour stimuler ou inhiber l'angiogenese et la cardiovascularisation | |
AU5920099A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
EP2042597B1 (fr) | Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse | |
JP2002543784A (ja) | 新規なチンパンジーエリスロポエチン(chepo)ポリペプチドおよびこれをコードする核酸 | |
EP1287161A2 (fr) | Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes | |
NZ532803A (en) | Promotion or inhibition of angiogenesis and cardiovascularization |